Eli Lilly price target raised to $1,150 from $1,050 at JPMorgan

JPMorgan analyst Chris Schott raised the firm’s price target on Eli Lilly (LLY) to $1,150 from $1,050 and keeps an Overweight rating on the shares after meetings with management. The firm says the meetings reinforced its positive view on the story. JPMorgan increasingly sees Lilly’s agreement with the Trump Administration expanding access to obesity medicines as a net positive. Incremental volumes will more than offset the price cuts, the analyst tells investors in a research note. This, coupled with ongoing U.S. market share gains and an underpenetrated international obesity opportunity, position Lilly for significant growth in 2026 and beyond, contends JPMorgan.